9 years of historical data (2016–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Precision BioSciences, Inc. trades at 4.0x earnings, 10% above its 5-year average of 3.7x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 83%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $51M | $26M | $42M | $105M | $434M | $434M | $583M | — | — | — |
| Enterprise Value | $-4993344 | $-29626299 | $-43346615 | $-60016821 | $300M | $355M | $402M | — | — | — |
| P/E Ratio → | 4.04 | 3.66 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.74 | 0.38 | 0.86 | 4.17 | 3.76 | 17.87 | 26.23 | — | — | — |
| P/B Ratio | 0.51 | 0.47 | 2.23 | 1.73 | 4.76 | 9.77 | 4.22 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.43 | -0.89 | -2.39 | 2.59 | 14.60 | 18.10 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | -3.31 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Precision BioSciences, Inc. earns an operating margin of -38.1%. Operating margins have expanded from -248.3% to -38.1% over the past 3 years, signaling improving operational efficiency. ROE of 19.0% indicates solid capital efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -38.1% | -38.1% | -89.8% | -248.3% | -34.1% | -452.2% | -392.1% | -440.2% | -338.9% | -125.8% |
| Net Profit Margin | 10.4% | 10.4% | -125.8% | -444.8% | -26.5% | -448.9% | -417.6% | -423.0% | -325.4% | -117.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.0% | 19.0% | -154.7% | -147.3% | -45.1% | -119.3% | -104.2% | -677.5% | — | — |
| ROA | 4.8% | 4.8% | -30.8% | -49.7% | -16.9% | -56.6% | -49.7% | -43.6% | -24.7% | -8.4% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
| ROCE | -22.6% | -22.6% | -30.3% | -35.2% | -27.8% | -69.6% | -52.4% | -51.0% | -28.6% | -9.8% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $86M exceeds total debt of $30M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.53 | 0.53 | 1.66 | 0.41 | 0.10 | 0.24 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -4.53 | -2.72 | -1.48 | -1.78 | -1.31 | -2.58 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -1.04 |
| Interest Coverage | -14.68 | -14.68 | -19.61 | -56.08 | -298.30 | — | -479.14 | — | — | — |
Net cash position: cash ($86M) exceeds total debt ($30M)
Short-term solvency ratios and asset-utilisation metrics
Precision BioSciences, Inc.'s current ratio of 6.34x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.34x to 6.34x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.34 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
| Quick Ratio | 6.34 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
| Cash Ratio | 5.76 | 5.76 | 2.33 | 3.18 | 3.99 | 2.10 | 6.72 | 7.33 | 6.82 | 11.20 |
| Asset Turnover | — | 0.50 | 0.30 | 0.11 | 0.55 | 0.16 | 0.09 | 0.08 | 0.09 | 0.07 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 9.02 | 95.87 | 10.47 | 1.54 | 150.30 | 15.84 | 17.54 | 1.24 | 20.08 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Precision BioSciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 24.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 24.8% | 27.3% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $4M | $3M | $2M | $2M | $1M | $2M | $1M | $17M |
Compare DTIL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| DTILYou | $51M | 4.0 | — | — | 100.0% | -38.1% | 19.0% | — | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how DTIL stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonPrecision BioSciences, Inc.'s current P/E ratio is 4.0x. The historical average is 3.7x. This places it at the 100th percentile of its historical range.
Precision BioSciences, Inc.'s return on equity (ROE) is 19.0%. The historical average is -91.9%.
Based on historical data, Precision BioSciences, Inc. is trading at a P/E of 4.0x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Precision BioSciences, Inc. has 100.0% gross margin and -38.1% operating margin.